key: cord-0705453-ey07rmgc authors: Bikdeli, Behnood; Madhavan, Mahesh V.; Jimenez, David; Chuich, Taylor; Dreyfus, Isaac; Driggin, Elissa; Nigoghossian, Caroline Der; Ageno, Walter; Madjid, Mohammad; Guo, Yutao; Tang, Liang V.; Hu, Yu; Giri, Jay; Cushman, Mary; Quéré, Isabelle; Dimakakos, Evangelos P.; Gibson, C. Michael; Lippi, Giuseppe; Favaloro, Emmanuel J.; Fareed, Jawed; Caprini, Joseph A.; Tafur, Alfonso J.; Burton, John R.; Francese, Dominic P.; Wang, Elizabeth Y.; Falanga, Anna; McLintock, Claire; Hunt, Beverley J.; Spyropoulos, Alex C.; Barnes, Geoffrey D.; Eikelboom, John W.; Weinberg, Ido; Schulman, Sam; Carrier, Marc; Piazza, Gregory; Beckman, Joshua A.; Steg, P. Gabriel; Stone, Gregg W.; Rosenkranz, Stephan; Goldhaber, Samuel Z.; Parikh, Sahil A.; Monreal, Manuel; Krumholz, Harlan M.; Konstantinides, Stavros V.; Weitz, Jeffrey I.; Lip, Gregory Y.H. title: COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up date: 2020-04-17 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2020.04.031 sha: 917798a8228960f65244fc232a05e4792cae1ac2 doc_id: 705453 cord_uid: ey07rmgc Abstract Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic. The coronavirus disease of 2019 (COVID-19) is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), now deemed a pandemic by the World Health Organization (1) (2) (3) . COVID-19 has a number of important cardiovascular implications (4) (5) (6) . Patients with prior cardiovascular disease are at higher risk for adverse events from COVID- 19 . Individuals without a history of cardiovascular disease are at risk for incident cardiovascular complications (5) . There are several ways in which the COVID-19 pandemic may affect the prevention and management of thrombotic and thromboembolic disease (hereafter collectively referred to as thrombotic disease for brevity). First, the direct effects of COVID-19 or the indirect effects of infection, such as through severe illness and hypoxia, may predispose patients to thrombotic events. Preliminary reports suggest that hemostatic abnormalities, including disseminated intravascular coagulation (DIC), occur in patients affected by COVID-19 (7, 8) . Additionally, the severe inflammatory response, critical illness, and underlying traditional risk factors may all predispose to thrombotic events, similar to prior virulent zoonotic coronavirus outbreaks (Table 1 ) (9, 10) . Second, investigational therapies for treating COVID-19 may have adverse drug-drug interactions with antiplatelet agents and anticoagulants. Third, the pandemic, because of resource allocations or social distancing recommendations, may adversely affect the care of patients without COVID-19 but who present with thrombotic events. For example, (mis)perception that antithrombotic agents confer increased risk for contracting COVID-19, may lead to untoward interruption of anticoagulation by some patients. The current manuscript, authored by an international collaborative of clinicians and investigators, summarizes the pathogenesis, epidemiology, treatment, and available outcome data related to thrombotic disease in patients with COVID-19, as well as management of thrombotic events in patients without COVID-19 during this pandemic. Although the focus is on the prevention and management of venous thromboembolism (VTE) and antithrombotic therapy for acute coronary syndromes (ACS), many of the recommendations are relevant to other conditions requiring antithrombotic therapy. We provide clinical guidance, when feasible, and also identify areas that require urgent attention for future research. Every effort was made to provide a comprehensive assessment of the published evidence (MEDLINE with PubMed interface, date of last search: April 12, 2020) . To accommodate the rapidly-evolving nature of information and concern for the delay between completion of studies and their publication, we also reviewed manuscripts on two pre-print servers (https://www.medrxiv.org/ and https://www.ssrn.com/index.cfm/en/coronavirus/, date of last search April 12, 2020) . We acknowledge that the manuscripts from the latter two sources are not peer-reviewed. There is international variability in preventive measures and testing strategies by local authorities, diagnostic tests availability, access to care and treatment strategies, as well as variability in outcome reporting for COVID-19. These issues influence the reported diagnosed cases, casualties, and in turn case-fatality rates. Moreover, to date, we lack large prospective cohorts. The existing evidence, including data on thrombotic complications, is derived primarily from small and retrospective analyses (Figure 1 ). The current document represents an effort to provide general guidance for patient-care related to thrombosis and antithrombotic therapy. Given the limitations of the evidence base, the steering committee (BB, MVM, JIW, SK, SZG, AT, MM, HMK, GYHL) chose several questions that seemed more challenging but relevant to patient care (11) . These questions were sent to the entire group of authors twice. The Delphi method was implemented to provide consensus-based guidance. The questions included considerations for prophylactic or therapeutic anticoagulant regimens among various subgroups of patients with COVID-19, and antithrombotic therapy in the setting of suspected or confirmed DIC. SARS-CoV2 is a single-strand RNA coronavirus, which enters human cells mainly by binding the angiotensin converting enzyme 2 (ACE2) (12) , which is highly expressed in lung alveolar cells, cardiac myocytes, the vascular endothelium, and other cells (1, 13) . SARS-CoV2 is transmitted primarily after viral particles are inhaled and enter the respiratory tract (1) . In addition, the virus can survive for 24-72 hours on surfaces, depending on the type of surface, which enables fomite transmission (14) . Initial symptoms of COVID-19 overlap with other viral syndromes, and include fever, fatigue, headache, cough, shortness of breath, diarrhea, headaches, and myalgias (15) (16) (17) . As with other virulent zoonotic coronavirus infections such as severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS-CoV), COVID-19 has the potential to result in severe illness including systemic inflammatory response syndrome, acute respiratory disease syndrome (ARDS), multi-organ involvement, and shock (18) . Although older age and comorbidities such as cardiovascular disease confer a higher risk for severe disease, young and otherwise healthy patients are also at risk for complications (19) . Common laboratory abnormalities found in patients with COVID-19 include lymphopenia (15) and elevation in lactate dehydrogenase and inflammatory markers such as, C-reactive protein, D-dimer, ferritin and interleukin-6 (IL-6) (20) . IL-6 levels may correlate with disease severity, and a procoagulant profile (21) . The most consistent hemostatic abnormalities with COVID-19 include mild thrombocytopenia (22) and increased D-dimer levels (23) , which are associated with a higher risk of requiring mechanical ventilation, intensive care unit [ICU] admission, or death. Data related to other tests are less certain and often contradictory (24, 25) . Disease severity is variably associated with prolongation of the prothrombin time (PT) and international normalized ratio (INR) (1, 20, 26) , and thrombin time (TT) (27) , and variably by a trend toward shortened activated partial thromboplastin time (aPTT) (1, 16, 19, 28) . Recently, Tang et al. (7) assessed 183 patients with COVID-19, 21 of whom (11.5%) died. Among the notable differences between patients who died and those who survived were increased levels of D-dimer and fibrin degradation products ([FDPs], ~3.5-and ~1.9-fold increase, respectively) and PT prolongation (by 14%, P<0.001). Further, 71% of COVID-19 patients who died fulfilled the International Society on Thrombosis and Haemostasis (ISTH) criteria (29) for DIC, compared with only 0.6% among survivors. Collectively, these hemostatic changes indicate some forms of coagulopathy that may predispose to thrombotic events (Central Illustration), although the cause is uncertain. Nevertheless, it is yet unknown whether these hemostatic changes are a specific effect of SARS-CoV-2 or are a consequence of cytokine storm that precipitates the onset of systemic inflammatory response syndrome (SIRS), as observed in other viral disease (30-33). Another consideration which has not yet been investigated is that the hemostatic changes seen with COVID-19 infection are related to liver dysfunction (34). A recent study reported 3 cases with severe COVID-19 and cerebral infarction, one associated with bilateral limb ischemia, in the setting of elevated antiphospholipid antibodies. Whether antiphospholipid antibodies play a major role in pathophysiology of thrombosis associated with COVID-19 requires further investigation (35). Elevated troponin levels are associated with poor outcomes in several studies of COVID-19 (36). However, the differential diagnosis for elevated troponin in COVID-19 is broad (37) and includes non-specific myocardial injury, impaired renal function (leading to troponin accumulation), myocarditis, pulmonary embolism (PE), and Type I and II myocardial infarction (MI) (38,39). Similarly, elevation of natriuretic peptides is non-specific (38), and consideration for thrombotic events (e.g., PE) should only be raised in the appropriate clinical context. Several investigational agents are being tested in the management of COVID-19, especially for patients who develop severe disease. Some of these drugs have clinically important interactions with antiplatelet or anticoagulant agents (Tables 4 and 5) . Further, a few of these investigational agents have been associated with excess risk (or, in other cases, reduced risk) for thrombotic events, or for thrombocytopenia in prior studies of non-COVID-19 populations. For example, bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), and is under investigational use for COVID-19, is associated with increased risk for adverse cardiovascular events, including MI, cerebrovascular accidents, and VTE (40,41). Alternatively, fingolimod, an immunomodulating agent being tried for COVID-19, may reduce reperfusion injury and improve outcomes in patients suffering from acute ischemic stroke (42). Hydroxychorloquine, recently receiving Emergency Use Authorization from the U.S. Food and Drug Administration for treatment of COVID-19, may potentially exert antithrombotic properties, especially against anti-phospholipid antibodies (43). Scientists are studying a number of agents for COVID-19 treatment that may have interactions with oral antiplatelet agents. Table 3 presents potential drug interactions between investigational drugs for COVID-19 and commonly administered oral antiplatelet agents. Lopinavir/ritonavir is a protease inhibitor and inhibits CYP3A4 metabolism. Although the active metabolite for clopidogrel is mostly formed by CYP2C19, inhibition of CYP3A4 may also lead to reduction in effective dosage of clopidogrel. In contrast, inhibition of CYP3A4 may increase effects of ticagrelor. Therefore, the concomitant use of these agents along with lopinavir/ritonavir should be cautioned. Although limited clinical data exist, use of P2Y 12 platelet function testing to guide the use of clopidogrel or ticagrelor in this setting might be considered. An alternative, in the absence of contraindications, is to use prasugrel, which is not prone to these interactions (44-47). Remdesivir, a nucleotide-analog inhibitor of RNA-dependent RNA polymerase, reportedly an inducer of CYP3A4; however, dose adjustments for oral antiplatelet agents are currently not recommended. Of note, there are no major drug-drug interactions between investigational COVID-19 therapies and parenteral antiplatelet agents such as cangrelor and glycoprotein IIb/IIIa inhibitors. Hospitalized patients with acute medical illness, including infections such as pneumonia, are at increased risk of VTE (48,49). Prophylactic anticoagulation reduces the risk of VTE in acutely ill hospitalized medical patients (50) (51) (52) , and appropriate use of VTE prophylaxis is covered in clinical practice guidelines (49, 53, 54) . Multiple risk stratification tools are available for VTE risk assessment in this setting (e.g. the Caprini, IMPROVE, and Padua models) (55-60). The choice of specific risk assessment model may vary across health system. However, similar to other acutely ill medical patients, VTE risk stratification for hospitalized patients with COVID-19 should be undertaken. A recent study from China, using the Padua model, reported that 40% of hospitalized patients with COVID-19 were at high risk of VTE. The study did not provide data about the use of VTE prophylaxis, or the incident VTE events (61). Hospitalized patients with COVID-19 who have respiratory failure or co-morbidities (e.g., active cancer, or heart failure) (62), patients who are bedridden, and those requiring intensive care should receive pharmacological VTE prophylaxis, unless there are contraindications. The choice of agents and dosing should be based on available guideline recommendations (53, 54, 63) . The World Health Organization interim guidance statement recommends prophylactic daily low-molecular weight heparins (LMWHs), or twice daily subcutaneous unfractionated heparin (UFH) (64) . If pharmacological prophylaxis is contraindicated, mechanical VTE prophylaxis (intermittent pneumatic compression) should be considered in immobilized patients (64, 65) . Missed doses of pharmacologic VTE prophylaxis are common and are likely associated with worse outcomes (66) . Therefore, every effort should be made to ensure that patients receive all scheduled doses of pharmacologic VTE prophylaxis. In this regard, once daily dosing regimen of LMWHs may be advantageous over UFH to reduce personal protective equipment (PPE) use and exposure of healthcare workers. Consideration for risk of VTE in pregnant patients with COVID-19 deserves further attention. The risk of VTE is increased during pregnancy and the postpartum period (67, 68) . Although limited data are available, pregnant women admitted to hospital with COVID-19 infection are likely to be at an increased risk of VTE. It is reasonable to assess the risk of VTE and to consider pharmacological thromboprophylaxis, especially if they have other VTE risk factors. Weight-adjusted prophylactic dosing of anticoagulation is an interesting topic that requires additional investigation (69) . After hospital discharge from acute medical illness, extended prophylaxis with LMWH (70) or direct oral anticoagulants (DOACs) (71) (72) (73) (74) can reduce the risk of VTE, at the cost of increase in bleeding events, including major bleeding (75, 76) . While no data specific to COVID-19 exist, it is reasonable to employ individualized risk stratification for thrombotic and hemorrhagic risk, followed by consideration of extended prophylaxis (for up to 45 days) for patients with elevated risk of VTE (e.g., reduced mobility, co-morbidities such as active cancer, and [according to some authors in the writing group], elevated D-dimer >2 times the upper normal limit) who have low risk of bleeding (74, 77, 78) . The role of thromboprophylaxis for quarantined patients with mild COVID-19 but significant co-morbidities, or for patients without COVID-19 who are less active because of quarantine is uncertain. These patients should be advised to stay active at home. In the absence of high-quality data, pharmacological prophylaxis should be reserved for those at highest risk patients, including those with limited mobility and history of prior VTE or active malignancy. As described above, elevated D-dimer levels, is a common finding in patients with COVID-19 (23), and does not currently warrant routine investigation for acute VTE in absence of clinical manifestations or other supporting information. However, the index of suspicion for VTE should be high in the case typical DVT symptoms, hypoxemia disproportionate to known respiratory pathologies, or acute unexplained right ventricular dysfunction. A diagnostic challenge arises among patients with COVID-19, as imaging studies used to diagnose DVT or PE may not be pursued given risk of transmitting infection to other patients or healthcare workers and potentially due to patient instability. Moreover, imaging studies may be challenging in the setting of patients with severe ARDS who require prone positioning. Investigation for PE is not feasible due to critical illness and prone position. Lower extremity ultrasound is also limited due to patient positioning. Deterioration of right ventricular function in this setting may be a critical finding, justifying the need for ways to diagnose and treat PE. However, it may be argued that the prognosis of patients with ARDS requiring prone position is so grave that investigation for underlying VTE may not alter the course. A potential option may be to consider echocardiography to assess for signs of potentially worsening right ventricular dysfunction and in rare circumstances, clot in transit (79). In view of the hemostatic derangements discussed above and observations from prior viral illnesses (80), some clinicians use intermediate-dose or full dose (therapeutic) parenteral anticoagulation (rather than prophylactic dosing) for routine care of patients with COVID-19 (81), hypothesizing that it may confer benefit to prevent microvascular thrombosis. However, the existing data are very limited, primarily based on a subgroup analysis (N=97) from a single retrospective study with limited control for potential confounders (82). A single center study from China suggested that D-dimer levels >1,500ng/mL has a sensitivity of 85.0% and specificity of 88.5% for detecting VTE events. However, the study was limited by small sample Few published studies have commented on incident VTE in patients with COVID-19. In a retrospective study from China, among 81 patients with severe COVID-19 admitted to ICU, 20 (25%) developed incident VTE. Of note, none of the patients had received VTE prophylaxis (85). In an preprint study of 25 patients with COVID-19 from Wuhan, who were suspected of having PE and underwent computed tomography angiography (CTA), 10 (40%) had evidence of acute PE on imaging (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548771); however, the study did not provide information related to use of VTE prophylaxis or the reason for performing CTA. In a study of 184 patients with severe COVID-19 from 3 academic medical centers in the Netherlands, the authors reported that 31% (95%CI 20-41) of patients developed incident VTE. All patients received pharmacological prophylaxis, although under-dosing was observed in 2 of the 3 participating centers (81). These findings require validation in additional studies. It is possible but unknown that VTE remains underdiagnosed in patients with severe COVID-19. This is important, as ARDS in patients with COVID-19 is, itself, a potential etiology for hypoxic pulmonary vasoconstriction, pulmonary hypertension and right ventricular failure. Further insult from PE may be unrecoverable. Therapeutic anticoagulation is the mainstay of VTE treatment (49, 86, 87) . Selection of an agent requires consideration of comorbidities such as renal or hepatic dysfunction, thrombocytopenia and gastrointestinal tract function, and the agent will likely change across the hospital course to the time of discharge. In many ill inpatients with VTE, parenteral anticoagulation (e.g. UFH) is preferred as it may be temporarily withheld and has no known drug-drug interactions with investigational COVID-19 therapies. Concerns with UFH, however, include the time to achieve therapeutic aPTT, and increased healthcare worker exposure for frequent blood draws. Therefore, LMWHs may be preferred in patients unlikely to need procedures. The benefit of oral anticoagulation with DOACs include the lack of need for monitoring, facilitation of discharge planning, and outpatient management. The potential risk (especially in the setting or organ dysfunction) may include clinical deterioration and lack of timely availability of effective reversal agents at some centers. For patients who are ready for discharge, DOACs or LMWH would be preferred to limit contact of patients with healthcare services required for INR monitoring for VKAs. Pulmonary embolism response teams (PERTs) allow for multidisciplinary care for patients intermediate and high-risk with VTE (49, (88) (89) (90) . During the COVID-19 pandemic, similar to other consultative services, PERTs should transition from in-person inpatient evaluation to e-consults using phone calls or telemedicine systems whenever feasible. It is important to note that, there are minimal available data demonstrating lower mortality from routine use of advanced VTE therapies (91, 92) . Therefore, the use of catheter-directed therapies during the current outbreak should be limited to the most critical situations. Indiscriminate use of inferior vena cava filters should be avoided (93) . Recurrent PE despite optimal anticoagulation, or clinically-significant VTE in the setting of absolute contraindications to anticoagulation would be among the few scenarios in which placement of an inferior vena cava filter may be considered (11) . Even after IVC filter placement, anticoagulation should be resumed as soon as feasible, and this is often done with gradually increasing doses and close observation for bleeding. With regard to reperfusion strategies for acute PE, current guideline recommendations should be followed. known COVID-19 positivity or uncertain status, rather than support strategies requiring the use of a catheterization laboratory or an operating room (95) . Figure 2 presents a potential algorithm for treatments based on risk due to VTE and COVID-19 severity. The vast majority of patients with symptomatic acute deep venous thrombosis (DVT), should be managed with anticoagulation, with home treatment whenever possible. The few that may require acute endovascular techniques (either local fibrinolysis or embolectomy) include those with phlegmasia, or truly refractory symptoms (96) . Myocardial injury in COVID-19, as evidenced by elevated cardiac troponin levels or electrocardiographic and echocardiographic abnormalities, is associated with severe disease. 7 Furthermore, higher troponin levels are associated with severe COVID-19 (5, 97) . However, not all such events are due to thrombotic ACS. While anecdotal cases of patients with COVID-19 presenting with ACS due to plaque-rupture have been described (type I MI), currently no such cases have been published. Such cases have been also previously described with influenza or other viral illnesses, and have been attributed to a combination of SIRS as well as localized vascular/plaque inflammation (10, 98, 99) . In presentations consistent with ACS due to plaque rupture (i.e. Type I MI) (39), dual antiplatelet therapy (DAPT) and full dose anticoagulation per American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC) guidelines should be administered unless there are contraindications (100) (101) (102) (103) . In patients with perceived elevated bleeding risk, regimens with less potent antiplatelet agents, such as with clopidogrel, should be considered given that hemorrhagic complications are not uncommon. Special attention should be also given to drug-drug interactions between antiplatelet agents or anticoagulants and COVID-19 investigational therapies. Parenteral antithrombotic agents, in general, do not have known major interactions with the COVID-19 investigational therapies (Tables 4, 5) . Angiography and Interventions (SCAI) recently provided guidance regarding catheterization laboratory procedures in the current climate (84,104). The recommendations note that it is reasonable to continue optimal medical therapy and defer non-urgent cardiac procedures, in order to preserve PPE, hospital resources including inpatient and ICU beds, and minimize exposure for patients and healthcare workers, alike. Prior to intervention, efforts should be made to distinguish non-specific myocardial injury, myocarditis, and true plaque rupture presentations (104) . A low threshold to use transthoracic echocardiography to identify wall motion abnormalities should be considered prior to catheterization laboratory activation. Even in case of STEMI, in which primary percutaneous coronary intervention (PCI) reduces mortality and reinfarction, risk of COVID-19 transmission from patients to healthcare workers, or vice versa (asymptomatic vectors) must be considered. In light of this, individual centers in China and elsewhere have developed adjusted ACS protocols, which call for consideration of fibrinolytic therapy in selected patients with STEMI (105) . Centers in which timely percutaneous coronary intervention is less feasible may be more likely to adopt such a strategy. However, given that presentations of COVID-19 can mimic ACS (e.g. in the setting of myocarditis), fibrinolytic therapy must be used with caution. The risk of VTE, which is increased in critically ill patients, is likely even higher in those with SARS-CoV-2 and critical illness. Aside from hemostatic derangements, immobility, an systemic inflammatory state, mechanical ventilation and central venous catheters contribute to VTE risk within the ICU (106-108), Nutritional deficiencies and liver dysfunction may also interfere with the production of coagulation factors (109) . Alterations in pharmacokinetics in critically ill patients may necessitate anticoagulation dose adjustment (110) , due to factors relating to absorption, metabolism, and renal (or hepatic) elimination of these drugs in the setting of potential organ dysfunction. Parenteral anticoagulation is recommended in most cases in which anticoagulant therapy is needed for known thrombotic disease. UFH can be used in the setting of anticipated procedures, or in patients with deteriorating renal function. If no urgent procedures are anticipated, LMWHs are a reasonable alternative (111) . In patients requiring ECMO, anticoagulation is frequently required to maintain circuit patency, especially at lower flow settings. Rates of complications are unknown in patients with SARS-CoV-2, but rates of thrombosis and hemorrhage may be as high as 53% and 16%, respectively, in other populations with respiratory failure (112) . The limited outcome data that are available for ECMO in patients with SARS-CoV-2 suggest poor outcomes, with 5 of 6 patients dying in one series and 3 out of 3 in another (113, 114) . There are currently insufficient data to recommend anticoagulation targets for COVID-19 patients requiring ECMO (115) . As previously mentioned, severe COVID-19 may predispose to DIC with such patients experiencing particularly poor outcomes (7) . Supportive care and addressing the underlying hypoxia or co-infection are appropriate (29) . There are insufficient data to recommend transfusion thresholds that differ from those recommended for other critically ill patients. If invasive procedures are planned, prophylactic transfusion of platelets, fresh frozen plasma, fibrinogen, and prothrombin complex concentrate may be considered (29) . Lastly, patients requiring targeted temperature management may exhibit prolongations of both PT and aPTT without evidence of bleeding diathesis (116) . Therefore, correction of coagulopathy in unselected patients without overt bleeding, is not currently recommended. DIC is common in many patients with critical illness (117) , including those with COVID-19 (7, 118) . It is uncertain whether COVID-19 has unique characteristics to cause direct activation of coagulation. The diagnosis of DIC is best established using the ISTH DIC score calculator (29) . Regular laboratory monitoring of platelet count, PT, D-dimer, and fibrinogen in patients with COVID-19 is important to diagnose worsening coagulopathy. The first step in management of DIC is to identify and treat the underlying condition(s). Bacterial superinfections should be treated aggressively. In addition to preventing VTE, LMWH prophylaxis may decrease thrombin generation and modify the course of DIC. Preliminary results, albeit with small number of events and limited adjustment, may suggest a favorable response from LMWH prophylaxis (82,118). Longacting antiplatelet agents should be generally discontinued in most patients with DIC, unless required (e.g. recent ACS or stent implantation). For patients with moderate or severe COVID-19 and an indication for dual antiplatelet therapy (e.g. PCI within the past 3 months or recent MI) and with suspected or confirmed DIC without overt bleeding, in the absence of evidence decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to continue dual antiplatelet therapy if platelet count ≥50,000, reduce to single antiplatelet therapy if 25,000≤platelet count<50,000, and discontinue if platelets <25,000. However, these guidelines may be revised upward or downward depending on the individualized relative risk of stentrelated thrombotic complications vs. bleeding. Recovery from DIC is dependent on endogenous fibrinolysis breaking down the disseminated thrombi. Clinically-overt bleeding is uncommon in the setting of COVID-19. However, when bleeding occurs in COVID-19-associated DIC, blood products support should be considered as per septic coagulopathy (119) . In summary, the mainstay of blood products transfusion are as follows: platelet concentrate to maintain platelet count >50 × 10 9 /L in DIC patients with active bleeding or >20 × 10 9 /L in those with a high risk of bleeding or requiring invasive procedures., The main goal of management for patients with known or new-onset thrombotic disease but without COVID-19 is to provide sufficient antithrombotic protection, while minimizing physical contact between patients and healthcare workers and health systems. Outpatient management or early discharge for acute VTE should be instituted when possible (120) (121) (122) , and early discharge after medication stabilization for low-risk ACS or PCI for high-risk ACS should be considered (100) (101) (102) . Telemedicine should be the preferred method of follow-up, and inperson visits should be reserved only for scenarios that cannot be addressed by telemedicine, or that may potentially warrant hospitalization. In general, pharmacotherapy in patients with known thrombotic disease and without COVID-19, should be followed similar to the period prior to the pandemic. Although a recent document from the CDC indicated an increased risk of severe COVID-19 in patients receiving "blood thinners" (123) , there is no evidence that antiplatelet agents or anticoagulants, increase the risk of contracting COVID-19, or of developing severe COVID-19. Sufficient education should be provided to patients for self-monitoring of symptoms, and to avoid unnecessary emergency department visits for nuisance bleeding. For patients receiving VKAs, frequent INR monitoring may pose logistical challenges due to lockdowns and may unnecessarily increase the risk of being exposed to SARS-CoV-2. Therefore, thoughtful considerations should be given to potential alternatives, including using extended INR testing intervals if prior INRs have been stable (124) . Other alternatives include home-based INR checks, if this can be set up promptly, drive-through INR testing, or switching to a DOAC or LMWHs when clinically appropriate (Figure 3) . A summary of key recommendations is presented in Table 6 . Considerations for healthcare workers. The CDC recommends contact and droplet personal PPE for healthcare workers in their routine care of patients with COVID-19. If an aerosol-generating procedure is being performed (e.g. intubation, extubation, cardiopulmonary resuscitation), additional airborne PPE with an N95 respirator is recommended. Use of telemedicine in place of in-person office visits is a strategy to minimize physical exposure. Further details have been discussed elsewhere (5, 104) . The following considerations specific to the care of patients with thrombotic disease may be useful. Over-the phone and telemedicine approaches should be considered for all non-urgent appointments. For necessary in-person visits, visitor restrictions and staggering of appointments are important considerations (125) . For patients with COVID-19 who require urgent procedures, such as interventions for ACS, high-risk PE, or critical limb ischemia, the fewest number of staff necessary should be involved. For patients without known infection, healthcare workers should screen patients for COVID-19 exposures or infectivity, consider appropriate PPE during the procedure, and apply disinfection techniques post-procedure, as outlined previously (126) . In patients who require, emergent cardiac catheterization with unknown COVID-19 status, airborne PPE with an N95 respirator and/or Powered Air Purifying Respirator is recommended (127, 128) . Active involvement of health systems with respect to the care of patients with thrombotic disease are critical to achieving good outcomes for both COVID-19-infected and uninfected patients. If feasible, resources should be allocated to enable at-home or drive-through INR checks. Further, system-based considerations should be made to monitor and make necessary adjustments to algorithms for management of suspected STEMI or severe PE requiring PERT teams. If procedures are deemed necessary for COVID-19 infected patients, specific protocols should be put into place regarding PPE use and room disinfection. (Figure 4) . The WHO and government agencies have recognized the critical importance of public health interventions at the societal level (including social distancing and self-isolation) to decrease transmission rates and alleviate the burden on health systems (129) . In the most affected areas, governments have enacted mandatory home quarantine for all non-essential personnel (130) (131) (132) . There are several important issues to consider as these interventions relate to thrombotic disease. First, given the recommendations to stay at home, with decreased daily activity and sedentary lifestyles, patients may be at increased risk for VTE (133) (134) (135) (136) (137) . Clinicians should be aware of this (especially in older adults and higher-risk patients) and provide education on the importance of home activities to mitigate this risk (138) . Second, as daily routines are disrupted, dietary changes (especially in daily intake of green vegetables, which are the major source of vitamin K in the Western diet) may affect patients who receive VKAs. As quarantine measures become more severe, changes in diet and vitamin K intake may impact INR values. Providers and patients should be aware of these risks, and patients should be advised to maintain stable diet to the best of their ability. Third, the COVID-19 pandemic has produced damaging economic effects (139) , with United Nations estimating that COVID-19 is likely to cost the world economy more than $2 trillion in 2020. These losses may adversely affect patients' treatment for thrombotic diseases. Socioeconomic disadvantage has been linked to higher rates of VTE and adverse outcomes (140, 141) . As the economic effects of COVID-19 continue to evolve, these communities may come under new and significant stress. More data and higher-quality data are required to learn how COVID-19 and thrombotic disease interact. Such data, ideally derived from prospective, multicenter, multinational studies, could help to elucidate the similarities and distinctions in disease presentation and outcomes of patients with COVID-19 and preexisting and incident thromboembolic disease, and help to identify management strategies to optimize outcomes in these patients. Currently, one large international registry of patients with venous thromboembolism (the Registro Informatizado and a dedicated adjudicated prospective registry to study COVID-19 and other cardiovascular outcomes is being initiated (CORONA-VTE, BWH Thrombosis Research Group; PI: G. Piazza). A multicenter multinational ACS registry is has begun and a new AHA registry for cardiovascular care and outcomes of these patients. Special attention should also be given to patients with pre-existing thromboembolic disease who have limited access to care in the face of the COVID-19 pandemic, which has hindered transportation and limited the resources of the healthcare system. Funding agencies, professional societies, and organizations with active patient participation will all play an important role when it comes to future research in this area. Funding agencies, including the National Institutes of Health (which has already responded swiftly) (143) should continue to pay specific attention to this pandemic. Coordination and cooperation are necessary to quickly address research priorities including those related to thrombotic disease ( Table 5) pandemic. Such guidance should supplement, rather than supplant, clinical decision-making. Nuances of conversations between patients and practitioners should be considered for appropriate patient-centered decisions. In conclusion, thrombotic disease may be precedent factors or incident complications in patients with COVID-19. Important considerations for the preventive and therapeutic use of antithrombotic agents should be kept in mind to mitigate the thrombotic and hemorrhagic events in these high-risk patients. Funding agencies, professional societies, patients, clinicians, and investigators should work collaboratively to effectively and efficiently address numerous critical areas of knowledge gap. thrombosis. • Initial series suggest the common occurrence of venous thromboembolic disease in patients with severe COVID-19. The optimal preventive strategy warrants further investigation. investigational COVID-19 therapies should be considered. Administer at 50% of dose (do not administer if initial dose is 2.5 mg twice daily) † Decrease dose to 80 mg once followed by 40 mg once daily Do not co-administer CYP3A4 and P-gp inhibition: Do not co-administer Other drugs being studied to treat COVID-19 include bevacizumab, chloroquine/hydroxychloroquine, eculizumab, fingolimod, losartan, and pirfenidone. Drug-drug interactions between these medications and oral anticoagulants have yet to be identified. Bevacizumab has been reported to cause deep vein thrombosis (9%), arterial thrombosis (5%) and pulmonary embolism (1%). It is also reported to cause thrombocytopenia (58%).*Parenteral anticoagulants (including unfractionated or low-molecular weight heparins, bivalirudin, argatroban, and fondaparinux) are non CYP metabolized and don't interact with any of the investigational agents # Reported with interferon alpha. †These recommendations are based on the U.S. package insert. The Canadian package insert considers the combination of these agents to be contraindicated. ‡Interferon has been reported to cause pulmonary embolism (<5%), thrombosis (<5%), decreased platelet count (1-15% with Alfa-2b formulation), and ischemic stroke (<5%). §Sarilumab has been reported to cause decreased platelet count, with decreases to less than 100,000 mm 3 in 1% an 0.7% of patients on 200 mg and 150 mg doses, respectively. CYP: Cytochrome P system. | To determine the optimal method for risk assessment for outpatients with mild COVID-19 who are at risk of VTE The options include the Caprini model, the IMPROVE model, and the Padua model, and others for assessment of the risk of VTE. These should be weighed against the risk of bleeding. To determine the incidence acute coronary syndromes in population-based studies Patients with Moderate or severe COVID-19 without DIC (hospitalized) To determine the incidence and predictors of VTE among patients with COVID-19 who present with respiratory insufficiency and/or hemodynamic instability. These include lower extremity DVTs, central-line associated DVT in upper or lower extremities, and also PE. Prospective multicenter cohort (observational) data needed, these protocols should not interfere and could run in parallel with interventional trials which are planned or already underway. To develop an appropriate algorithm for the diagnosis of incident VTE in patients with COVID-19. D-dimer is elevated in many inpatients with COVID-19, although negative value may still be helpful. In some cases of COVID-19 with worsening hypoxemia, CTPA may be considered instead of non-contrast CT (which only assesses the pulmonary parenchyma. Unresolved issues include diagnostic tests for critically-ill patients, including those in prone position, with limited options for CTPA or ultrasonography. To determine the optimal total duration of prophylactic anticoagulation Ultrasound screening in select patients may need to be studied. To determine the optimal dose of prophylactic anticoagulation in specific populations (e.g. those with obesity or advanced kidney disease) Weight-adjusted prophylactic dosing for patients with obesity, or dosing based on creatinine clearance in patients with kidney disease require further investigation. To determine if LMWH constitutes the preferred method of pharmacological prophylaxis To determine the optimal method for risk stratification and VTE prophylaxis after hospital discharge The options include the Caprini model, the IMPROVE model, and the Padua model, and others for assessment of the risk of VTE. These should be weighed against the risk of bleeding. To determine if routine use of higher doses of anticoagulants (i.e. higher than prophylactic doses as described in the international guidelines), confer net benefit An important question would be whether monitoring anti-Xa activity would be preferable over aPTT. To determine the incidence and predictors of type I acute myocardial infarction in patients with COVID-19, and to compare their process measures and outcomes with non-infected patients. To determine the potential role of agents including danaparoid, fondaparinux, and sulodexide in select patients with moderate/severe COVID-19. To determine if routine use of pharmacological VTE prophylaxis or low or standard dose anticoagulation with UFH or LMWH is warranted (if no overt bleeding) A relevant question is whether prophylactic, or other, dose anticoagulation should be given to patients with DIC who do not have bleeding, even without immobility To determine if additional clinical characteristics and variables in the setting of DIC (e.g. lymphopenia) should be considered to help risk-stratify and assess prognosis To determine utility of other interventions including antithrombin concentrates. Patients without COVID-19 but with co-morbidities, and homebound during the pandemic To determine the optimal method of screening and risk stratification for consideration of VTE prophylaxis The options include the Caprini model, the IMPROVE model, and the Padua model, and others for assessment of the risk of VTE. These should be weighed against the risk of bleeding. To conduct population-level studies to determine the trends in incidence and outcomes of thrombotic disease in the period of reduced office visits Although telemedicine is reasonable to control the COVID-19 pandemic, potential adverse consequences on non-communicable disease, including thrombotic disease deserve investigation. aPTT: activated partial thromboplastin time, COVID-19: Coronavirus disease 2019; CTPA: computed tomography pulmonary angiography; LMWH: low-molecular weight heparin; PE: pulmonary embolism; VTE: Venous thromboembolism Patients with Mild COVID-19 (outpatient) For outpatients with mild COVID-19, increased mobility should be encouraged. Although indiscriminate use of pharmacological VTE prophylaxis should not be pursued, assessment for the risk of VTE and of bleeding is reasonable. Pharmacologic prophylaxis could be considered after risk assessment on an individual case basis for patients who have elevated risk VTE, without high bleeding risk.* There is no known risk of developing severe COVD-19 due to taking antithrombotic agents (i.e. antiplatelet agents or anticoagulants). If patients have been taking antithrombotic agents for prior known thrombotic disease, they should continue their antithrombotic agents as recommended. For outpatients on vitamin K antagonists who do not have recent stable INRs, and are unable to undergo home or drive-through INR testing, it is reasonable to transition the treatment DOACs if there are no contraindications and no problems with drug availability and affordability. If DOACs are not approved or available, low-molecular weight heparin can be considered as alternative.* Patients with Moderate or Severe COVID-19 without DIC (hospitalized) Hospitalized patients with COVID-19 should undergo risk stratification for VTE prophylaxis. For hospitalized patients with COVID-19 and not in DIC, prophylactic doses of anticoagulation can be administered to prevent VTE.*¥ † If pharmacological prophylaxis is contraindicated, it is reasonable to consider intermittent pneumatic compression. For hospitalized patients with COVID-19 and not in DIC, there is insufficient data to consider routine therapeutic or intermediate-dose parenteral anticoagulation with UFH or LMWH.* ‡ Routine screening for VTE (e.g. bilateral lower extremity ultrasound) for hospitalized patients with COVID-19 with elevated D-Dimer (>1,500 ng/mL) cannot be recommended at this point & Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized) For patients with moderate or severe COVID-19 and in DIC but without overt bleeding, prophylactic anticoagulation should be administered.*¥ § For hospitalized patients with COVID-19 with suspected or confirmed DIC, but no overt bleeding, there is insufficient data to consider routine therapeutic or intermediate-dose parenteral anticoagulation with UFH or LMWH.*β For patients with moderate or severe COVID-19 on chronic therapeutic anticoagulation, who develop suspected or confirmed DIC without overt bleeding, it is reasonable to consider the indication for anticoagulation and weigh with risk of bleeding when making clinical decisions regarding dose adjustments or discontinuation. The majority of authors of this manuscript recommended reducing the intensity of anticoagulation in this clinical circumstance, unless the risk of thrombosis considered to be exceedingly high. || For patients with moderate or severe COVID-19 and an indication for dual antiplatelet therapy (e.g. percutaneous coronary intervention within the past 3 months or recent myocardial infarction) and with suspected or confirmed DIC without overt bleeding, in the absence of evidence, decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to continue dual antiplatelet therapy if platelet count >50,000, reduce to single antiplatelet therapy if 25,000